Wenjing Xu

2 months ago | advanced.onlinelibrary.wiley.com | Hongyue Tian |Hang Zhou |Lu Zhang |Wenjing Xu

Conflict of Interest The authors declare no conflict of interest. Supporting Information Filename Description adfm202422867-sup-0001-SuppMat.docx591.3 KB Supporting Information References 1, , , , , , , , , , , , , , , J. Am. Chem. Soc. 2024, 146, 12011. 2, , , , , , , , , , , , Adv. Mater. 2024, 36, 2400342. 3, , , , , , , , , , Nat. Energy. 2024, 9, 975. 4, , , , , , , , , Chem. Eng. J. 2023, 471, 144711. 5, , , , , , , , , , , , , , , , , , ACS Energy Lett. 2023, 8, 4104.

Jun 5, 2024 | nature.com | Alan Baer |Wan-Fai Ng |Chiara Baldini |Teresa K Tarrant |Athena Papas |Valérie Devauchelle-Pensec | +8 more

Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease with no approved disease-modifying therapies. Dazodalibep (DAZ), a novel nonantibody fusion protein, is a CD40 ligand antagonist that blocks costimulatory signals between T and B cells and antigen-presenting cells, and therefore may suppress the wide spectrum of cellular and humoral responses that drive autoimmunity in SjD. This study was a phase 2, randomized, double-blinded, placebo (PBO)-controlled trial of DAZ with a crossover stage in two distinct populations of participants with SjD. Population 1 had moderate-to-severe systemic disease activity and population 2 had an unacceptable symptom burden and limited systemic organ involvement. All participants had a diagnosis of SjD, with 21.6% and 10.1% having an associated connective tissue disease (rheumatoid arthritis or systemic lupus erythematosus) in populations 1 and 2, respectively. The remaining participants would be considered as having primary Sjögren’s syndrome. The primary endpoint for population 1 (n = 74) was the change from baseline in the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index at day 169. The primary endpoint for population 2 (n = 109) was the change from baseline in the European League Against Rheumatism Sjögren’s Syndrome Patient Reported Index at day 169. The primary endpoints (least squares mean ± standard error) were achieved with statistical significance for both population 1 (DAZ, −6.3 ± 0.6; PBO, −4.1 ± 0.6; P = 0.0167) and population 2 (DAZ, −1.8 ± 0.2; PBO, −0.5 ± 0.2; P = 0.0002). DAZ was generally safe and well tolerated. Among the most frequently reported adverse events were COVID-19, diarrhea, headache, nasopharyngitis, upper respiratory tract infection, arthralgia, constipation and urinary tract infection. In summary, DAZ appears to be a potential new therapy for SjD and its efficacy implies an important role for the CD40/CD40 ligand pathway in its pathogenesis. ClinicalTrials.gov identifier: NCT04129164 . In a phase 2 trial of dazodalibep, a CD40 ligand, with a crossover stage in two distinct populations of patients with Sjögren’s disease, the compound was well tolerated and led to significantly improved disease activity.

Mar 25, 2024 | pubs.rsc.org | Wenjing Xu |Wei Li |Wei Chen |Mei Lan Liu

In situ formed nickel phosphide/iron oxide heterojunction for accelerating hydrogen generation Designing cost-effective catalysts with structural features and necessary functionality to drive ammonia borane hydrolysis for hydrogen generation remains a challenge. In this work, a close heterojunction of Fe3O4-Ni2P uniformly embedded in amorphous carbon material (Fe3O4-Ni2P@C) has been prepared via surface-phosphorization.

Feb 22, 2024 | mdpi.com | Qiong Wang |Wei Zhang |Wenjing Xu |Hongmei Zhang

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.